Charles River Laboratories Intl. Inc Expected to Earn FY2018 Earnings of $5.93 Per Share (CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Equities researchers at Mitsubishi UFJ Financial Group increased their FY2018 earnings per share (EPS) estimates for Charles River Laboratories Intl. in a research report issued on Wednesday, November 7th. Mitsubishi UFJ Financial Group analyst J. Twizell now anticipates that the medical research company will post earnings per share of $5.93 for the year, up from their prior forecast of $5.90. Mitsubishi UFJ Financial Group also issued estimates for Charles River Laboratories Intl.’s Q4 2018 earnings at $1.40 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company had revenue of $585.30 million during the quarter, compared to analyst estimates of $567.58 million. During the same quarter last year, the business posted $1.30 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 26.1% compared to the same quarter last year.

Several other brokerages have also issued reports on CRL. Raymond James upgraded shares of Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research note on Thursday, August 23rd. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th. SunTrust Banks raised their price target on shares of Charles River Laboratories Intl. to $135.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Robert W. Baird raised their price target on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research note on Monday, September 17th. Finally, Royal Bank of Canada upgraded shares of Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price target for the company in a research note on Tuesday, July 17th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $130.56.

Shares of CRL stock opened at $136.10 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.72 and a debt-to-equity ratio of 1.52. Charles River Laboratories Intl. has a 12-month low of $96.70 and a 12-month high of $138.89. The company has a market cap of $6.01 billion, a PE ratio of 25.83, a P/E/G ratio of 1.57 and a beta of 0.74.

In related news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $120.05, for a total value of $149,942.45. Following the completion of the transaction, the insider now directly owns 13,690 shares in the company, valued at approximately $1,643,484.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David P. Johst sold 23,356 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the completion of the transaction, the insider now owns 219,849 shares of the company’s stock, valued at $29,899,464. The disclosure for this sale can be found here. Insiders sold a total of 28,671 shares of company stock valued at $3,829,160 over the last quarter. 2.10% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in CRL. First Trust Advisors LP grew its stake in Charles River Laboratories Intl. by 56.7% in the 3rd quarter. First Trust Advisors LP now owns 858,962 shares of the medical research company’s stock valued at $115,565,000 after buying an additional 310,975 shares in the last quarter. BlackRock Inc. grew its stake in Charles River Laboratories Intl. by 7.0% in the 2nd quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after buying an additional 292,685 shares in the last quarter. Bank of Montreal Can boosted its holdings in Charles River Laboratories Intl. by 1,910.1% in the 3rd quarter. Bank of Montreal Can now owns 221,355 shares of the medical research company’s stock valued at $29,781,000 after purchasing an additional 210,343 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Charles River Laboratories Intl. by 51.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 396,451 shares of the medical research company’s stock valued at $53,339,000 after purchasing an additional 134,594 shares during the period. Finally, Monarch Partners Asset Management LLC bought a new position in Charles River Laboratories Intl. in the 3rd quarter valued at $14,587,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Find a Trading Strategy That Works

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply